GOODWILL AND INTANGIBLE ASSETS

12 Months Ended

Mar. 28, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Effective as of March 31, 2019, the Company revised the composition of its reportable segments to align with its three global business units, Plasma, Blood Center and Hospital. Refer to Note 18, Segment and Enterprise-Wide Information, for additional information regarding the change in the Company's reportable segments.

A reporting unit is defined as an operating segment or one level below an operating segment, referred to as a component. The Company aggregates components within an operating segment that have similar economic characteristics. Consistent with its reportable segments, reporting units for purposes of assessing goodwill impairment have also been reorganized based on business unit and include: Plasma, Blood Center and Hospital.

To determine the amount of goodwill within each of the new reporting units, the Company reallocated, on a relative fair value basis, $84.0 million of goodwill previously allocated to the former Europe, APAC and Japan reporting units to the new global reporting units. In addition, the $126.8 million of goodwill previously allocated to the former North America reporting units was reallocated to each new respective global reporting unit.

The following represents the Company's goodwill balance by new global reportable segment for fiscal 2020 and 2019. The prior period information has been restated to conform to the current presentation:



(In thousands)	Plasma		Blood Center			Hospital			Total
Carrying amount as of March 31, 2018	$	28,979	$	36,782		$	145,634		$	211,395
Currency translation	—		(116		)	(460		)	(576		)
Carrying amount as of March 30, 2019	28,979		36,666			145,174			210,819
Currency translation	—		(34		)	(133		)	(167		)
Carrying amount as of March 28, 2020	$	28,979	$	36,632		$	145,041		$	210,652

The results of the Company's goodwill impairment test performed in the fourth quarter of fiscal 2020, 2019 and 2018 indicated that the estimated fair value of all reporting units exceeded their respective carrying values. There were no reporting units at risk of impairment as of the fiscal 2020, 2019 and 2018 annual test dates.

The gross carrying amount of intangible assets and the related accumulated amortization as of March 28, 2020 and March 30, 2019 is as follows:



(In thousands)	Gross Carrying Amount		Accumulated Amortization		Net
As of March 28, 2020
Amortizable:
Patents	$	9,878	$	8,653	$	1,225
Capitalized software	76,740		43,022		33,718
Other developed technology	138,283		81,822		56,461
Customer contracts and related relationships	193,797		158,890		34,907
Trade names	5,141		4,555		586
Total	$	423,839	$	296,942	$	126,897
Non-amortizable:
In-process software development	$	2,563
In-process patents	3,646
Total	$	6,209



(In thousands)	Gross Carrying Amount		Accumulated Amortization		Net
As of March 30, 2019
Amortizable:
Patents	$	9,635	$	8,444	$	1,191
Capitalized software	66,631		34,737		31,894
Other developed technology	103,321		73,271		30,050
Customer contracts and related relationships	194,793		142,747		52,046
Trade names	5,169		4,280		889
Total	$	379,549	$	263,479	$	116,070
Non-amortizable:
In-process software development	$	8,740
In-process patents	2,883
Total	$	11,623

Intangible assets include the value assigned to license rights and other developed technology, patents, customer contracts and relationships and trade names. The estimated useful lives for all of these intangible assets are approximately 5 to 15 years. The changes to the net carrying value of the Company's intangible assets from March 30, 2019 to March 28, 2020 reflect the impact of amortization expense, partially offset by the investment in capitalized software.

Aggregate amortization expense for amortized intangible assets for fiscal 2020, 2019, and 2018 was $34.2 million, $32.6 million and $31.9 million, respectively. There were no intangible asset impairments during fiscal 2020, 2019, and 2018.

Future annual amortization expense on intangible assets is estimated to be as follows:



(In thousands)
Fiscal 2021	$	27,604
Fiscal 2022	$	26,892
Fiscal 2023	$	12,098
Fiscal 2024	$	9,350
Fiscal 2025	$	4,966

For costs incurred related to the development of software to be sold, leased, or otherwise marketed, the Company applies the provisions of ASC Topic 985-20, Software - Costs of Software to be Sold, Leased or Marketed, which specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers. The costs capitalized for each project are included in intangible assets in the consolidated financial statements.

The Company capitalized $3.9 million and $3.5 million in software development costs for ongoing initiatives during fiscal 2020 and 2019, respectively. At March 28, 2020 and March 30, 2019, the Company had a total of $79.3 million and $75.4 million of software costs capitalized, of which $2.6 million and $8.7 million are related to in process software development initiatives, respectively, and the remaining balance represents in-service assets that are being amortized over their useful lives.